A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction

Abstract Maternal vaccines to prevent infant Group B Streptococcus (GBS) disease have progressed through phase II development and may be licensed based on immunologic endpoints, which have yet to be approved by regulatory authorities. Here we present a multistate case control study to characterize t...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Julia C. Rhodes, Rebecca Kahn, Shanna Bolcen, Nong Shang, Yunmi Chung, Monica M. Farley, Amber N. Britton, Ashley E. Moore, Stepy Thomas, Joelle Nadle, Laura B. Amsden, Jacek Skarbinski, Kristi R. VanWinden, Meghan Barnes, Kerianne Engesser, Patricia Ferrieri, AmberJean P. Hansen, Lee H. Harrison, Laura Jeffrey, Jessica L. Nyholm, Sean T. O’Leary, Courtney Olson-Chen, Jemma V. Rowlands, Shannon A. Seopaul, Ann R. Thomas, Htet Htet N. Wrigley, Lesley McGee, Sundaram Ajay Vishwanathan, Fahmina Akhter, Bailey Alston, Lily Tao Jia, Yikun Li, Palak Y. Patel, Joy Rivers, Jessica E. Southwell, Theresa Tran, Panagiotis Maniatis, Stephanie J. Schrag
Format:	Artigo
Język:	Inglês
Wydane:	Nature Portfolio 2025-10-01
Seria:	Nature Communications
Dostęp online:	https://doi.org/10.1038/s41467-025-64324-y
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!